By Endpoints News
A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.
